Schimmelpennink Evert B. 4

What Happened Evert B. Schimmelpennink, President, CEO, Secretary and a director of LENZ Therapeutics, purchased 28,089 shares in an open-market transaction on 2026-03-27. The filing reports a weighted average price of $8.95 per share for a total reported value of $251,411. This transaction is coded P (purchase).

Key Details

• Transaction date: 2026-03-27; weighted average price reported as $8.95; total reported value $251,411.
• Footnote: purchases occurred in the price range $8.80 to $9.25; the reporting person offered to provide the exact number of shares bought at each price upon request.
• Shares owned after the transaction: not disclosed in the provided filing.
• Filing date (Form 4): 2026-03-30. No late-filing flag was indicated in the provided data.

Context This was a straight open-market purchase (code P). Purchases by a company’s CEO are factual data points that some investors view as a positive signal, but they do not, by themselves, explain the insider’s motivations. The footnote clarifies the reported $8.95 figure is a weighted average across multiple execution prices.